- Home
- SEVN vs RCEL Comparison
SEVN vs RCEL Comparison
Compare SEVN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- RCEL
- Stock Information
- Founded
- SEVN 1986
- RCEL N/A
- Country
- SEVN United States
- RCEL United States
- Employees
- SEVN N/A
- RCEL N/A
- Industry
- SEVN Real Estate Investment Trusts
- RCEL Medical/Dental Instruments
- Sector
- SEVN Real Estate
- RCEL Health Care
- Exchange
- SEVN Nasdaq
- RCEL Nasdaq
- Market Cap
- SEVN 161.4M
- RCEL 140.5M
- IPO Year
- SEVN N/A
- RCEL N/A
- Fundamental
- Price
- SEVN $10.08
- RCEL N/A
- Analyst Decision
- SEVN Strong Buy
- RCEL Strong Buy
- Analyst Count
- SEVN 2
- RCEL 4
- Target Price
- SEVN $13.50
- RCEL $13.75
- AVG Volume (30 Days)
- SEVN 45.2K
- RCEL 1.3M
- Earning Date
- SEVN 10-27-2025
- RCEL 11-06-2025
- Dividend Yield
- SEVN 11.17%
- RCEL N/A
- EPS Growth
- SEVN N/A
- RCEL N/A
- EPS
- SEVN 1.04
- RCEL N/A
- Revenue
- SEVN $29,272,000.00
- RCEL $74,884,000.00
- Revenue This Year
- SEVN N/A
- RCEL $22.92
- Revenue Next Year
- SEVN N/A
- RCEL $37.07
- P/E Ratio
- SEVN $9.63
- RCEL N/A
- Revenue Growth
- SEVN N/A
- RCEL 38.32
- 52 Week Low
- SEVN $10.01
- RCEL $3.60
- 52 Week High
- SEVN $14.66
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- SEVN 29.10
- RCEL 54.48
- Support Level
- SEVN $10.24
- RCEL $5.03
- Resistance Level
- SEVN $10.49
- RCEL $5.64
- Average True Range (ATR)
- SEVN 0.24
- RCEL 0.34
- MACD
- SEVN -0.07
- RCEL 0.01
- Stochastic Oscillator
- SEVN 6.33
- RCEL 49.00
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.